Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

MORRISON & FOERSTER WINS 10TH CIRCUIT DISMISSAL OF SECURITIES CLASS ACTION AGAINST MEDICAL DEVICE COMPANY

Published by Gbaf News

Posted on October 29, 2014

Featured image for article about Top Stories

AspenBio Pharma had been accused of misleading investors over prospects for appendicitis test; MoFo partners Raj Chatterjee and Mark Foster follow up 2012 district court win with appeals court affirmation

Morrison & Foerster won the complete dismissal of a securities class action against medical diagnostics company AspenBio Pharma with the ruling on October 17, 2014, at the Tenth Circuit Court of Appeals affirming a district court dismissal in 2012.

Raj Chatterjee

San Francisco-based litigation partners Jim Brosnahan, Raj Chatterjee and Mark Foster led the Morrison & Foerster team, which had represented Castle Rock, Colo.-based AspenBio (renamed Venaxis in 2012) since the suit, Wolfe v. AspenBio, was filed in 2010.

Plaintiffs alleged that AspenBio and certain officers misled investors about preliminary testing results for an appendicitis diagnostic in development, as well as about the viability, uniqueness, and potential applications of the product and its prospects for approval by the Food and Drug Administration. The diagnostic is initially being developed for children, adolescents, and young adults and is designed to assist doctors in ruling out appendicitis without the use of CT scans, particularly in an emergency room setting.

In 2012 Messrs. Chatterjee and Foster filed a successful motion for dismissal in Colorado district court, and had previously obtained a stay of a parallel shareholder derivative lawsuit. The plaintiffs challenged the dismissal on appeal, and Mr. Chatterjee presented oral argument before the Tenth Circuit in September 2013.

“We are thrilled that the Tenth Circuit has upheld the dismissal of this class action against our client Venaxis. We’ve been challenging these cases since 2010 and have obtained dismissals at every stage, beginning at the trial level and now prevailing at the appellate stage,” said Mr. Chatterjee. “With the litigation resolved, Venaxis can continue to focus on growing a company and developing a product that could substantially advance the public health.”